C3, Equipmed sign distribution agreements
Monday, 27 October, 2003
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
The ReCell agreement will be activated once TGA approval has been obtained for general marketing of the product. The agreements have three year terms and including marketing and support activities.
C3 CEO Troels Jordansen said the company was pleased to have an agreement with Equipmed, which has experience in the plastic and cosmetic surgery market and distributes tissue engineering products from international company Isolagen.
C3 is planning to expand its business internationally next year, with a European production facility in the works and sales of ReCell in 15 companies around the world expected.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
